Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):33–41. doi: 10.1097/QAI.0000000000000668

Table 2.

Darunavir pharmacokinetic parameters, presented as median (interquartile range) or number/total (%)

	DRV/r800/100mg Once Daily			DRV/r 600/100 mg Twice Daily
	2^nd trim (n=15)	3^rd trim (n=30)	PP (n=23)	2^nd trim (n=13)	3^rd trim (n=34)	PP (n=27)
AUC (μg*hr/mL)	64.6^* (35.9, 72.3)	63.5^* (46.0, 75.2)	103.9 (85.9, 135.7)	45.8^* (36.1, 53.4)	45.9^* (29.3, 52.5)	61.7 (49.7, 80.9)
Met AUC target^#/total	9/15^* (60%)	19/30^* (63%)	22/24 (92%)	7/13 (54%)	19/34^* (56%)	22/27 (81%)
Cmax (μ/mL)	6.77^* (4.35, 7.84)	5.78^* (4.31, 7.29)	8.11 (6.93, 10.30)	5.64^* (3.78, 6.07)	5.53^* (4.44-7.10)	7.78 (6.11-9.54)
Clast (hours)	0.99^* (0.43,1.81)	1.17^* (0.73 -1.72)	2.78 (2.05, 2.98)	2.12 (1.76, 2.85)	2.22 (1.68-3.26)	2.51 (2.04, 3.27)
Cl/F (L/hr)	12.4^* (11.1, 22.9)	12.6^* (10.6, 17.4)	7.7 (5.9, 9.3)	13.1^* (11.2, 16.6)	13.1^* (11.4, 20.5)	9.5 (7.4-11.7)

^*

p<0.05, compared to postpartum, Wilcoxon signed-rank test

^#

AUC minimum targets were AUC_0-24 of at least 56.5 μg*h/mL for once daily dosing and AUC_0-12 of at least 43.6 μg*h/mL for twice daily dosing